Cingulate Inc. cotiza a 4.84 USD y tiene una capitalización bursátil de $70M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clin…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.95 | $-0.84 | $-1.35 | $-1.09 |
| Estimado | $-0.53 | $-1.55 | $-0.75 | $-0.82 |
| Sorpresa | -79.2% | +45.8% | -80.0% | -32.9% |
| Métrica | CING | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -894.8% | -40.4% | -854.4% |
| ROA | -148.9% | -32.0% | -116.9% |
| Current Ratio | 1.16 | 2.84 | -1.68 |
| Debt / Equity | 0.46 | 0.28 | +0.18 |